Webinar Date/Time: Thu, Mar 2, 2023 1:00 PM EST
Improve patient engagement and retention for genomics-based clinical trials. Learn how a well-planned genetic screening program can lead to successful patient screening and recruitment.
Register Free: https://www.pharmtech.com/pt/genomics
Event Overview:
Genomics-based clinical trials often target a very small subset of a patient population, which makes finding and recruiting patients extremely challenging. Implementing effective engagement and retention strategies are critical. A well-planned genetic screening program can be a key difference between trial success and failure.
Kelly Athman, M.S., CGC, Sr. Director of Medical Affairs at InformedDNA—the leading applied genomics solutions provider for pharmaceutical and biotech companies conducting clinical trials in the U.S.—will share strategies to maximize genomics-based clinical trial success.
Key Learning Objectives:
Who Should Attend:
Speaker
Kelly Athman, MS, CGC
Senior Director, Medical Affairs
InformedDNA
Kelly Athman, MS, CGC is a board-certified genetic counselor with more than 15 years of experience in the healthcare industry. Passionate about increasing patient access to high-quality genomics care drives her as the senior director of medical affairs at InformedDNA. Having worked directly with patients and families who experience the impact of having limited therapeutic options for rare genetic conditions fuels her work and enables Kelly to bring a unique clinical perspective on the promise of genomics-based treatments. Prior to joining InformedDNA, she served as a genetic counselor for Fairview Hospitals and Clinics, Children’s Mercy Hospital, and CentraCare Health Systems. Kelly holds an M.S. in Molecular, Cellular, Developmental Biology & Genetics and a B.A. in Psychology and Biology from the University of Minnesota
Register Free: https://www.pharmtech.com/pt/genomics
New Survey Uncovers Distrust as Key Factor in Enrollment Declines Among Black Patients
October 2nd 2024Findings from two Baltimore medical centers presented at the American Society for Radiation Oncology Annual Meeting suggest spiritual themes and distrust may be behind the decline in trial participation.